Chronisch obstruktive Lungenerkrankung: Pathophysiologie, Diagnostik und Therapie

Sebastian Fähndrich; Philipp M. Lepper; Robert Bals

doi:10.1055/s-0034-1370291

Innere Medizin up2date, Table of Contents

Dtsch Med Wochenschr 2014; 2(03): 193-210
DOI: 10.1055/s-0034-1370291

Atmungsorgane

Chronisch obstruktive Lungenerkrankung: Pathophysiologie, Diagnostik und Therapie

Chronic obstructive pulmonary disease: pathophysiology, diagnosis, and therapy

Authors

Sebastian Fähndrich
Philipp M. Lepper
Robert Bals

Abstract

All articles of this category

Full Text

References

Literatur
1 Vogelmeier C, Buhl R, Criee CP et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin]. Pneumologie 2007; 61: e1-40
2 Fähndrich S, Guttmann C, Bals R. [Chronic obstructive pulmonary disease: pathophysiology, diagnosis, and therapy]. Dtsch Med Wochenschr 2011; 136: 1847-1860
3 Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750
4 Lopez AD, Mathers CD, Ezzati M et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757
5 Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733-743
6 Schroth S, Koczulla R, Herr C et al. [Alpha-1-antitrypsin deficiency: diagnosis and therapy of the lung disease]. Pneumologie 2009; 63: 335-341
7 Hunninghake GM, Cho MH, Tesfaigzi Y et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608
8 Kohansal R, Martinez-Camblor P, Agusti A et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10
9 Doll R, Peto R, Wheatley K et al. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994; 309: 901-911
10 Agusti A, Calverley PM, Celli B et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122
11 Kohansal R, Martinez-Camblor P, Agusti A et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10
12 Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest 2008; 118: 394-402
13 Finkelstein R, Fraser RS, Ghezzo H et al. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-1672
14 Saetta M, Baraldo S, Corbino L et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717
15 O’Shaughnessy TC, Ansari TW, Barnes NC et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857
16 Di SA, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285
17 Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653
18 Herr C, Beisswenger C, Hess C et al. Suppression of pulmonary innate host defence in smokers. Thorax 2009; 64: 144-149
19 Sethi S, Sethi R, Eschberger K et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361
20 Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365
21 Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357
22 Montuschi P, Collins JV, Ciabattoni G et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177
23 Muller KC, Welker L, Paasch K et al. Lung fibroblasts from patients with emphysema show markers of senescence in vitro. Respir Res 2006; 7: 32
24 Voelkel NF, Douglas IS, Nicolls M. Angiogenesis in chronic lung disease. Chest 2007; 131: 874-879
25 Lee SH, Goswami S, Grudo A et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569
26 Greulich T, Koczulla R, Vogelmeier C et al. [Chronic obstructive pulmonary disease (COPD) as a systemic disease]. Dtsch Med Wochenschr 2009; 134: 1231-1235
27 Calverley PM, Anderson JA, Celli B et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719-725
28 Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519
29 Donaldson GC, Hurst JR, Smith CJ et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097
30 Barr RG, Bluemke DA, Ahmed FS et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227
31 de Voogd JN, Wempe JB, Koeter GH et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135: 619-625
32 Hung WW, Wisnivesky JP, Siu AL et al. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 134-137
33 Mannino DM. COPD and lung cancer have come a long way … baby. Am J Respir Crit Care Med 2007; 176: 108-109
34 Young RP, Hopkins RJ, Christmas T et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34: 380-386
35 Bertoletti L, Quenet S, Mismetti P et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012; 39: 862-868
36 Vogelmeier C, Buhl R, Criee CP et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Pneumologie 2007; 61: e1-40
37 Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012
38 Jones RC, Donaldson GC, Chavannes NH et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180: 1189-1195
39 Drummond MB, Hansel NN, Connett JE et al. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1301-1306
40 Weitzenblum E, Sautegeau A, Ehrhart M et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498
41 Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-279
42 Martinez FJ, Boscia J, Feldman G et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respir Med 2013; 107: 550-559
43 Jones PW, Singh D, Bateman ED et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40: 830-836
44 D’Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12: 156
45 Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209
46 Rabe KF, Bateman ED, O’Donnell D et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571
47 Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456
48 Mentz RJ, Wojdyla D, Fiuzat M et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013; 111: 582-587
49 Magnussen H, Kirsten AM, Kohler D et al. [Guidelines for long-term oxygen therapy. German Society for Pneumology and Respiratory Medicine]. Pneumologie 2008; 62: 748-756
50 Anonymous American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900
51 Fishman A, Martinez F, Naunheim K et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073
52 Valipour A, Herth FJ, Burghuber OC et al. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. Eur Respir J 2014; 43: 387-396
53 Windisch W, Brambring J, Budweiser S et al. [Non-invasive and invasive mechanical ventilation for treatment of chronic respiratory failure. S2-Guidelines published by the German Medical Association of Pneumology and Ventilatory Support]. Pneumologie 2010; 64: 207-240
54 Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; CD000146
55 Hurt RD, Sachs DP, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-1202
56 Potts LA, Garwood CL. Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm 2007; 64: 1381-1384
57 Andreas S, Batra A, Behr J et al. [Guidelines for smoking cessation in patients with COPD issued by the Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin]. Pneumologie 2008; 62: 255-272
58 Lacasse Y, Martin S, Lasserson TJ et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. Eura Medicophys 2007; 43: 475-485
59 Wijkstra PJ, Ten Vergert EM, van Altena R et al. Long term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 824-828
60 Griffiths TL, Burr ML, Campbell IA et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368
61 Behnke M, Jorres RA, Kirsten D et al. Clinical benefits of a combined hospital and home-based exercise programme over 18 months in patients with severe COPD. Monaldi Arch Chest Dis 2003; 59: 44-51
62 Puhan MA, Busching G, Schunemann HJ et al. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145: 816-825
63 Dhein Y, Munks-Lederer C, Worth H. [Evaluation of a structured education programme for patients with COPD under outpatient conditions – a pilot study]. Pneumologie 2003; 57: 591-597
64 Wildman MJ, Sanderson C, Groves J et al. Predicting mortality for patients with exacerbations of COPD and Asthma in the COPD and Asthma Outcome Study (CAOS). QJM 2009; 102: 389-399
65 Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607
66 Leuppi JD, Schuetz P, Bingisser R et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231